Goldman Sachs analyst Rajan Sharma suspended the firm’s investment rating, price target and earnings estimates for Idorsia (IDRSF) Pharmaceuticals with “insufficient information on which to base an investment view.” The company has stated it needs additional funding as its liquidity does not cover its negative cash flow for the next twelve months of its business plan, the analyst noted.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDRSF: